Rythmol

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved January 1998

Specific Treatments:

Paroxysmal atrial fibrillation

Therapeutic Areas

Find Related Trials for The Following Conditions

General Information

Rymol (propafenone hydrochloride) has been approved for use in patients without structural heart disease, for prolongation of the time to recurrence of paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardia associated with disabling symptoms. The drug has been marketed in the U.S. since 1990 for patients with life-threatening ventricular arrhythmias.

Clinical Results

In a 12-month study, patients' time to recurrence of paroxysmal atrial fibrillation/flutter, or sudden arrhythmic attacks, was eight times longer in patients receiving Rythmol versus patients treated with placebo.